Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA was delisted on the 25th of September, 2023.
43 hedge funds and large institutions have $146M invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2016 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 18 increasing their positions, 11 reducing their positions, and 5 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
64% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 11
37% more capital invested
Capital invested by funds: $106M → $146M (+$39.7M)
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
2% more funds holding
Funds holding: 42 → 43 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.58M |
| 2 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$1.45M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.04M |
| 4 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
+$934K |
| 5 |
OWD
Osborn Williams & Donohoe
Cincinnati,
Ohio
|
+$933K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$2.03M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.41M |
| 3 |
Goldman Sachs
New York
|
-$924K |
| 4 |
SIM
Spark Investment Management
New York
|
-$677K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$323K |
RETA Hedge Fund Activity: Q3 2016 in Review
43 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) for Q3 2016, worth a combined $146M — up 37% from $106M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new RETA positions and 5 closed out — a net gain of 1 holder — while 18 added to existing stakes and 11 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.58M. The largest seller was JP Morgan Chase, cutting an estimated $2.03M.
- 43 institutional investors held Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) as of Q3 2016, up from 42 in Q2 2016.
- Funds reported $146M of Reata Pharmaceuticals, Inc. Class A Common Stock stock for Q3 2016, up 37% quarter-over-quarter.
- 6 funds opened new Reata Pharmaceuticals, Inc. Class A Common Stock positions in Q3 2016 and 5 closed out, a net change of +1 holder.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock buyer in Q3 2016 was Vanguard Group, an estimated $1.58M added.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock seller in Q3 2016 was JP Morgan Chase, an estimated $2.03M sold.
Based on aggregated 13F filings for Q3 2016.